Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

338 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A clarion to recommit and reaffirm burn rehabilitation.
Richard RL, Hedman TL, Quick CD, Barillo DJ, Cancio LC, Renz EM, Chapman TT, Dewey WS, Dougherty ME, Esselman PC, Forbes-Duchart L, Franzen BJ, Hunter H, Kowalske K, Moore ML, Nakamura DY, Nedelec B, Niszczak J, Parry I, Serghiou M, Ward RS, Holcomb JB, Wolf SE. Richard RL, et al. Among authors: hunter h. J Burn Care Res. 2008 May-Jun;29(3):425-32. doi: 10.1097/BCR.0b013e318171081d. J Burn Care Res. 2008. PMID: 18388581 Review.
Burn survivors' perceptions of rehabilitation.
Yohannan SK, Ronda-Velez Y, Henriquez DA, Hunter H, Tufaro PA, Marren M, Sher M, Gorga DI, Yurt RW. Yohannan SK, et al. Among authors: hunter h. Burns. 2012 Dec;38(8):1151-6. doi: 10.1016/j.burns.2012.07.009. Epub 2012 Aug 24. Burns. 2012. PMID: 22922009
Burn camp: a positive experience for volunteer counselors.
Alden NE, Hunter H, Rabbitts A, Yurt RW. Alden NE, et al. Among authors: hunter h. J Burn Care Res. 2006 Nov-Dec;27(6):809-12. doi: 10.1097/01.BCR.0000245416.20898.A1. J Burn Care Res. 2006. PMID: 17091075 No abstract available.
Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple sclerosis (StarMS): protocol for a randomised controlled trial.
Brittain G, Petrie J, Duffy KEM, Glover R, Hullock K, Papaioannou D, Roldan E, Beecher C, Bursnall M, Ciccarelli O, Coles AJ, Cooper C, Giovannoni G, Gabriel I, Kazmi M, Kyriakou C, Nicholas R, Paling D, Peniket A, Scolding N, Silber E, de Silva T, Venneri A, Walters SJ, Young C, Muraro PA, Sharrack B, Snowden JA; StarMS trial team. Brittain G, et al. BMJ Open. 2024 Feb 5;14(2):e083582. doi: 10.1136/bmjopen-2023-083582. BMJ Open. 2024. PMID: 38316583 Free PMC article.
Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations.
Russell NH, Wilhelm-Benartzi C, Othman J, Dillon R, Knapper S, Batten LM, Canham J, Hinson EL, Betteridge S, Overgaard UM, Gilkes A, Potter N, Mehta P, Kottaridis P, Cavenagh J, Hemmaway C, Arnold C, Freeman SD, Dennis M; PORTEC Study Group. Russell NH, et al. J Clin Oncol. 2024 Apr 1;42(10):1158-1168. doi: 10.1200/JCO.23.00943. Epub 2024 Jan 12. J Clin Oncol. 2024. PMID: 38215358 Clinical Trial.
338 results